Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Positive Developments on COVID-19 Treatment Front

Positive Developments on COVID-19 Treatment Front.

Mark Vickery headshot

Moderna (MRNA) Covid Drug Proves 94.5% Efficacy

The company now intends on filing for emergency authorization in the United States. Shares are up for MRNA 14% in the early market on the news.

David Borun headshot

The S&P Hits a New High and the Dow Eyes Its Own 30K Milestone

Stocks continue to rally broadly on more good vaccine news, even as Covid-19 cases and deaths spike.

Daniel Laboe headshot

Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch

There is now a more defined light at the end of this pandemic tunnel. Still, we are not out of the woods yet.

Moderna (MRNA) Surges: Stock Moves 6.5% Higher

Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Sanghamitra Saha headshot

3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

AstraZeneca's (AZN) Calquence Fails in Coronavirus Study

AstraZeneca's (AZN) BTK inhibitor drug Calquence fails to achieve the main goal in the phase II CALAVI studies for patients hospitalized with respiratory symptoms of COVID-19.

Moderna (MRNA) Up on Coronavirus Vaccine Candidate Progress

Moderna ((MRNA) is set for the first interim analysis of its late-stage coronavirus vaccine study. Positive data may support an emergency use authorization by the end of 2020. Stock up.

Pfizer (PFE) to Supply 200M Doses of COVID-19 Vaccine to EU

Pfizer (PFE) and BioNTech sign a supply deal with the European Union for up to 300 million doses of their coronavirus vaccine.

Mark Vickery headshot

Equilibrium Descends on Mixed Market Indexes: AAPL, DIS & More

The re-balancing from a big rush out of tech into cyclical stocks earlier this week was in play Wednesday.

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson

Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day

Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day

Ritujay Ghosh headshot

Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success

Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.

Kinjel Shah headshot

Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy

Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.

Tirthankar Chakraborty headshot

2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine

Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.

Positive News on COVID-19 Vaccine

Positive News on COVID-19 Vaccine

Mark Vickery headshot

Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX

A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.

Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances

Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.

Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View

Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.

Company News for Oct 30, 2020

Companies in The News Are: NFLX, MRNA, IPHI, MRVL, RL.

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of -37.21% and 103.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

John Blank headshot

Update on the COVID Vaccine Race

A 2021 Macro Recovery is About This, Alone.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.

The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna

The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $70.53 in the latest trading session, marking a -0.44% move from the prior day.